NLRP1

NACHT, LRR and PYD domains-containing protein 1 · Q9C000 · NLRP1 on Sugi Atlas →

15,342 patent compounds predicted against NLRP1, 11,857 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dithiazanine (SCHEMBL22877)	1.00	1/20
SCHEMBL63594	1.00	1/20
Dithiazanine (SCHEMBL77427)	1.00	1/20
Perhexiline (SCHEMBL123149)	1.00	1/20
Perhexiline (SCHEMBL123150)	1.00	1/20
Iodide (SCHEMBL139369)	1.00	1/20
Dithiazanine (SCHEMBL142280)	1.00	1/20
SCHEMBL310460	1.00	1/20
Iodide (SCHEMBL335663)	1.00	1/20
SCHEMBL562469	1.00	1/20
Alazanine (SCHEMBL142862)	0.92	1/20
SCHEMBL554191	0.91	1/20
Ammonia Solution, Strong (SCHEMBL562468)	0.87	1/20
SCHEMBL707839	0.87	1/20
SCHEMBL63373	0.83	1/20
SCHEMBL710424	0.83	1/20
SCHEMBL711570	0.83	1/20
SCHEMBL711571	0.83	1/20
SCHEMBL129968	0.82	1/20
SCHEMBL555032	0.80	1/20

Clinical trials — most relevant to NLRP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate	PHASE4	NOT_YET_RECRUITING
Colchicine in Acutely Decompensated HFREF	PHASE4	RECRUITING
Cardiotoxicity in Breast Cancer Patients	PHASE4	RECRUITING
Colchicine for Symptom and Inflammation in Knee Osteoarthritis	PHASE2/PHASE3	COMPLETED
The Açaí Berry COVID-19 Anti-Inflammation Trial	PHASE2	UNKNOWN
Disulfiram in Rheumatoid Arthritis	PHASE2	NOT_YET_RECRUITING
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Nucleotide Protein -3 in Epileptic Children	nan	UNKNOWN
Effect of Low Dose of Colchicine on Platelet Reactivity	nan	COMPLETED
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.	nan	UNKNOWN
Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery	nan	WITHDRAWN
Inflammasomes in Cell Death in FTMH, ERM, and RRD	nan	COMPLETED
Evaluation of Inflammasome Gene Polymorphisms in Periodontitis Patients	nan	UNKNOWN
Gluten-related Disorders in Familial Mediterranean Fever Patients	nan	COMPLETED
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis	nan	SUSPENDED
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis	nan	COMPLETED
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood	nan	COMPLETED
(NOD)-Like Receptors CARD Domain-Containing 4 Levels in Individuals With Periodontitis	nan	UNKNOWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients	nan	COMPLETED
Extremes of Coronary Artery Disease and Normality:CAD Extremes	nan	RECRUITING
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1	nan	UNKNOWN
Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Megakaryocyte Heterogeneity in Sickle Cell Disease	nan	NOT_YET_RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients	nan	UNKNOWN
Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NLRP1 binder may also engage these)

Protein	Name	Similarity
D9I2G4	—	0.993	D9I2G4 →
D9I2H0	—	0.992	D9I2H0 →
D9I2G3	—	0.992	D9I2G3 →
D9I2G1	—	0.992	D9I2G1 →
Q2LKV2	—	0.992	Q2LKV2 →
Q86W26	—	0.991	Q86W26 →
P59047	—	0.991	P59047 →
Q8WX94	—	0.991	Q8WX94 →
Q647I9	—	0.990	Q647I9 →
D9I2F9	—	0.989	D9I2F9 →
Q2LKU9	—	0.988	Q2LKU9 →
Q2LKV5	—	0.987	Q2LKV5 →
Q0GKD5	—	0.986	Q0GKD5 →
P59046	—	0.986	P59046 →
Q8R4B8	—	0.985	Q8R4B8 →
B0FPE9	—	0.985	B0FPE9 →
P59044	—	0.985	P59044 →
NLRP3	NACHT, LRR and PYD domains-containing protein 3	0.984	landscape →
Q2LKW6	—	0.984	Q2LKW6 →
E9Q5R7	—	0.984	E9Q5R7 →
D4A523	—	0.984	D4A523 →
Q96MN2	—	0.982	Q96MN2 →
A1Z198	—	0.981	A1Z198 →
Q86W28	—	0.981	Q86W28 →
Q9R1M5	—	0.980	Q9R1M5 →
Q9NX02	—	0.980	Q9NX02 →
Q288C4	—	0.980	Q288C4 →
O15553	—	0.979	O15553 →
Q6B966	—	0.978	Q6B966 →
Q86W25	—	0.977	Q86W25 →